Increased expression but not sensitivity to Fas/CD95 in glioblastoma cells depleted of mitochondrial DNA

Liang,Bertrand  C.

doi:10.3892/etm.2010.158

Increased expression but not sensitivity to Fas/CD95 in glioblastoma cells depleted of mitochondrial DNA

Authors:
- Bertrand C. Liang
View Affiliations

Affiliations: Pfenex Inc., San Diego, CA 92121; and Department of Medicine, Division of Human Medical Genetics, University of Vermont College of Medicine, Burlington, VT 05405, USA
Published online on: September 29, 2010 https://doi.org/10.3892/etm.2010.158
Pages: 1049-1055

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitochondria and Fas (CD95) play a role in tumorigenicity and apoptosis. In the present study, the functional relationship of mitochondria to Fas in mediating apoptosis was investigated. Glioblastoma cells (DBTRG-O5MG, U87) were depleted of mitochondrial DNA (mtDNA) by treatment with ethidium bromide (Rho- cells). Compared to Rho+ cells, Rho- cells showed enhanced expression of Fas at the cell surface. Indeed, when Rho+ cells were treated with mitochondrial respiratory chain complex inhibitors, Fas cell surface expression was noted to increase in a similar fashion to the depletion of mtDNA in both cell lines. However, when cells were evaluated for sensitivity to apoptosis using Fas-engagement, there was no difference between the Rho+ and Rho- cells in either cell line. By contrast, sensitivity to the cytotoxic agent cis‑diammine-dichloroplatinum (cisplatin) was markedly increased in the Rho- cells, which expressed higher levels of cell surface Fas. Expression of Fas is increased with the depletion of mtDNA and respiratory complex inhibitors. However, this increase in expression does not necessarily translate to an increase in sensitivity to Fas-engagement, although there is an increase in the sensitivity of depleted cells to cytotoxic agents such as cisplatin.

View Figures

View References

1.	Henkart PA and Grinstein S: Apoptosis: mitochondria resurrected? J Exp Med. 183:1293–1295. 1996. View Article : Google Scholar : PubMed/NCBI
2.	Kroemer G, Zamzami N and Susin SA: Mitochondrial control of apoptosis. Immunol Today. 18:44–51. 1997. View Article : Google Scholar
3.	Green DR and Reed JC: Mitochondria and apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI
4.	Cavalli LR and Liang BC: Mutagenesis, tumorigenicity and apoptosis: are the mitochondria involved? Mutat Res. 398:19–26. 1998. View Article : Google Scholar : PubMed/NCBI
5.	Newmeyer DD, Farschon DM and Reed JC: Cell-free apoptosis in Xenopus egg extracts: inhibition by Bel-2 and requirement for an organelle fraction enriched in mitochondria. Cell. 79:353–364. 1994. View Article : Google Scholar : PubMed/NCBI
6.	Vayssiere JL, Petit PX, Risler Y and Mignotte B: Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc Natl Acad Sci USA. 91:11752–11756. 1994. View Article : Google Scholar : PubMed/NCBI
7.	Cossarizza A, Franceschi C, Monti D, et al: Protective effect of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: the role of mitochondria. Exp Cell Res. 220:232–240. 1995. View Article : Google Scholar : PubMed/NCBI
8.	Petit PX, Lecoeur H, Zorn E, et al: Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J Cell Biol. 130:157–167. 1995. View Article : Google Scholar : PubMed/NCBI
9.	Castedo M, Macho A, Zamzani N, et al: Mitochondrial perturbations define lymphocytes undergoing apoptotic depletion in vivo. Eur J Immunol. 25:3277–3284. 1995. View Article : Google Scholar : PubMed/NCBI
10.	Zamzami N, Marchetti P, Castedo M, et al: Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 182:367–377. 1995. View Article : Google Scholar
11.	Zamzami N, Marchetti P, Castedo M, et al: Mitochondrial control of nuclear apoptosis. J Exp Med. 183:1533–1544. 1996. View Article : Google Scholar : PubMed/NCBI
12.	Shimizu S, Eguchi Y, Kamiike W, et al: Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors. Oncogene. 13:21–29. 1996.
13.	Susin SA, Zamzami N, Castedo M, et al: Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med. 184:1331–1341. 1996. View Article : Google Scholar : PubMed/NCBI
14.	Zamzami N, Marchetti P, Castedo M, et al: Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett. 384:53–57. 1996. View Article : Google Scholar : PubMed/NCBI
15.	Boise LH and Thompson CB: Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc Natl Acad Sci USA. 94:3759–3764. 1997. View Article : Google Scholar : PubMed/NCBI
16.	Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 3:614–620. 1997. View Article : Google Scholar : PubMed/NCBI
17.	Stuart RA and Neupert W: Apocytochrome c: an exceptional mitochondrial precursor protein using an exceptional import pathway. Biochimie. 72:115–121. 1990. View Article : Google Scholar : PubMed/NCBI
18.	Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
19.	Mancini M, Nicholson DW, Roy S, et al: The caspase-3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signaling. J Cell Biol. 140:1485–1495. 1998. View Article : Google Scholar : PubMed/NCBI
20.	Susin SA, Lorenzo HK, Zamzani N, et al: Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 397:441–446. 1999. View Article : Google Scholar : PubMed/NCBI
21.	Susin SA, Lorenzo HK, Zamzani N, et al: Mitochondrial release of caspase-2 and -9 during the apoptotic process. J Exp Med. 189:381–394. 1999. View Article : Google Scholar : PubMed/NCBI
22.	D'Amelio M, Tino E and Cecconi F: The apoptosome emerging insights and new potential targets for drug design. Pharm Res. 25:740–751. 2008.PubMed/NCBI
23.	Bossy-Wetzel E, Newmeyer DD and Green DR: Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J. 17:37–49. 1998. View Article : Google Scholar
24.	Suzuki A, Tsutomi Y, Yamamoto N, Shibutani T and Akahane K: Mitochondrial regulation of cell death: mitochondria are essential for procaspase 3-p21 complex formation to resist Fas-mediated cell death. Mol Cell Biol. 19:3842–3847. 1999.PubMed/NCBI
25.	Trauth BC, Klas C, Peters AM, et al: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:301–305. 1989. View Article : Google Scholar : PubMed/NCBI
26.	Leithauser F, Dhein J, Mechtersheimer G, et al: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 69:415–429. 1993.
27.	Moller P, Koretz K, Leithauser F, et al: Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer. 57:371–377. 1994. View Article : Google Scholar : PubMed/NCBI
28.	Weller M, Malipiero U, Rensing-Ehl A, Barr PJ and Fontana A: Fas/APO-1 gene transfer for human malignant glioma. Cancer Res. 55:2936–2944. 1955.PubMed/NCBI
29.	Nagata S and Golstein P: The Fas death factor. Science. 267:1449–1456. 1995. View Article : Google Scholar
30.	French LE, Hahne M, Viard I, et al: Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol. 133:335–343. 1996. View Article : Google Scholar : PubMed/NCBI
31.	Houghton JA, Harwood FG, Gibson AA and Tillman DM: The fas signaling pathway is functional in colon carcinoma cells and induces apoptosis. Clin Cancer Res. 3:2205–2209. 1997.PubMed/NCBI
32.	Mahmood Z and Shulka Y: Death receptors: targets for cancer therapy. Exp Cell Res. 316:887–899. 2010. View Article : Google Scholar : PubMed/NCBI
33.	Itoh N and Nagata S: A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem. 268:10932–10937. 1993.PubMed/NCBI
34.	Cheng J, Zhou T, Liu C, et al: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 263:1759–1762. 1994. View Article : Google Scholar : PubMed/NCBI
35.	Sato T, Irie S, Kitada S and Reed JC: FAP-1: a protein tyrosine phosphatase that associates with Fas. Science. 268:411–415. 1995. View Article : Google Scholar : PubMed/NCBI
36.	Hughes SJ, Nambu Y, Soldes OS, et al: Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 57:5571–5578. 1997.PubMed/NCBI
37.	Irmler M, Thorne M, Hahne M, et al: Inhibition of death receptor signals by cellular FLIP. Nature. 388:190–195. 1997. View Article : Google Scholar : PubMed/NCBI
38.	Rokhlin OW, Bishop GA, Hostager BS, et al: Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 57:1758–1768. 1997.PubMed/NCBI
39.	Tillman DM, Harwood FG, Gibson AA and Houghton JA: Expression of genes that regulate Fas signalling and Fas-mediated apoptosis in colon carcinoma cells. Cell Death Differ. 5:450–457. 1998. View Article : Google Scholar : PubMed/NCBI
40.	Owen-Schaub LB, Radinsky R, Kruzel E, Berry K and Yonehara S: Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 54:1580–1586. 1994.PubMed/NCBI
41.	Holmstrom TH, Tran SE, Johnson VL, et al: Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol Cell Biol. 19:5991–6002. 1999.PubMed/NCBI
42.	Scaffidi C, Fulda S, Srinivasan A, et al: Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1675–1687. 1998. View Article : Google Scholar : PubMed/NCBI
43.	Heerdt BG, Houston MA and Augenlicht LH: Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ. 8:523–532. 1997.PubMed/NCBI
44.	Jacobson MD, Burne JF, King MP, et al: Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature. 361:365–369. 1993. View Article : Google Scholar : PubMed/NCBI
45.	Jacobson MD and Raff MC: Programmed cell death and Bcl-2 protection in very low oxygen. Nature. 374:814–816. 1995. View Article : Google Scholar : PubMed/NCBI
46.	Shimizu S, Eguchi Y, Kosaka H, et al: Prevention of hypoxia-induced cell death by Bcl-2 and Bel-xL. Nature. 374:811–813. 1995. View Article : Google Scholar : PubMed/NCBI
47.	Gamen S, Anel A, Montoya J, et al: mtDNA-depleted U937 cells are sensitive to TNF and Fas-mediated cytotoxicity. FEBS Lett. 376:15–18. 1995. View Article : Google Scholar : PubMed/NCBI
48.	Marchetti P, Susin SA, Decaudin D, et al: Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res. 56:2033–2038. 1996.PubMed/NCBI
49.	Schulze-Osthoff K, Beyaert R, Vandevoorde V, Haegeman G and Fiers W: Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J. 12:3095–3104. 1993.PubMed/NCBI
50.	Cavalli LR, Varella-Garcia M and Liang BC: Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ. 8:1189–1198. 1997.PubMed/NCBI
51.	Liang BC and Ullyatt E: Increased sensitivity to cis-diamminedichloroplatinum induced apoptosis with mitochondrial DNA depletion. Cell Death Differ. 5:694–701. 1998. View Article : Google Scholar : PubMed/NCBI
52.	Liang BC and Ullyatt E: Chemosensitization of glioblastoma cells to bis-dichloroethyl nitrosourea with tyrphostin AG17. Clin Cancer Res. 4:773–781. 1998.PubMed/NCBI
53.	King MP and Attardi G: Isolation of human cell lines lacking mitochondrial DNA. Methods Enzymol. 264:304–313. 1996. View Article : Google Scholar : PubMed/NCBI
54.	Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 139:271–279. 1991. View Article : Google Scholar : PubMed/NCBI
55.	Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT and Thompson CB: Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell. 91:627–637. 1997.PubMed/NCBI
56.	Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA and Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:314–317. 1992. View Article : Google Scholar
57.	Nagata S and Suda T: Fas and Fas ligand: 1pr and gld mutations. Immunol Today. 16:39–43. 1995. View Article : Google Scholar
58.	Wong GH and Goeddel DV: Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J Immunol. 152:1751–1755. 1994.PubMed/NCBI
59.	Shima Y, Nishimoto N, Ogata A, et al: Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood. 85:757–764. 1995.PubMed/NCBI
60.	Westendorf JJ, Lammert JM and Jelinek DF: Expression and function of Fas (APO 1/CD95) in patient myeloma cells and myeloma cell lines. Blood. 85:3566–3576. 1995.PubMed/NCBI
61.	Danielson SR, Wong A, Carelli V, Martinuzzi A, Schapira AH and Cortopassi GA: Cells bearing mutations causing Leber's hereditary optic neuropathy are sensitized to Fas-Induced apoptosis. J Biol Chem. 277:5810–5815. 2002.
62.	Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE and Geilen CC: The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptis. J Invest Dermatol. 117:333–340. 2001. View Article : Google Scholar : PubMed/NCBI
63.	Maas C, Verbrugge I, De Vries E, Savich G, van de Kooij LW, Tait SW and Borst J: Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogencity of Type I tumor cells after TRAIL receptor stimulation. Cell Death Differ. 17:1613–1623. 2010. View Article : Google Scholar : PubMed/NCBI
64.	Friesen C, Herr I, Krammer PH and Debatin KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 2:574–577. 1996. View Article : Google Scholar : PubMed/NCBI
65.	Matsumoto Y, Hayakawa A, Tamada Y, Mori H and Ohashi M: Upregulated expression of Fas antigen on cultured human keratinocytes with induction of apoptosis by cisplatin. Arch Dermatol Res. 288:267–279. 1996. View Article : Google Scholar : PubMed/NCBI
66.	Fulda S, Sieverts H, Friesen C, Herr I and Debatin KM: The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57:3823–3829. 1997.PubMed/NCBI
67.	Muller M, Strand S, Hug H, et al: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 99:403–413. 1997. View Article : Google Scholar : PubMed/NCBI
68.	Eischen CM, Kottke TJ, Martins LM, et al: Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 90:935–943. 1997.PubMed/NCBI
69.	Villunger A, Egle A, Kos M, et al: Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of' Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 57:3331–3334. 1997.PubMed/NCBI
70.	Verbrugge I, Maas C, Heijkoop M, Verheij and Borst J: Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/FAS via c-FLIP downregulation. Cell Death Differ. 17:551–561. 2010. View Article : Google Scholar : PubMed/NCBI
71.	Asoh S, Mori T, Hayashi J and Ohta S: Expression of the apoptosis-mediator Fas is enhanced by dysfunctional mitochondria. J Biochem. 120:600–607. 1996. View Article : Google Scholar : PubMed/NCBI